Please login to the form below

Not currently logged in

GSK wins sports contract

GSK has signed a contract with the World Anti-Doping Agency to help detect drugs that have performance-enhancing potential in sport

GlaxoSmithKline (GSK) has signed a deal with the World Anti-Doping Agency (WADA) to help scientists develop early detection methods for drugs that have performance-enhancing potential in sport.

GSK will supply WADA with confidential information about medicines in early stage development that may be abused by athletes once they are licensed. The deal covers all new drugs being developed by GSK.

The company said: "Scientists will look for any similarity to the pharmacological characteristics of existing performance-enhancing substances and assess how they work in the human body, this would include stimulatory effects or improved physical endurance."

New drugs found to have performance-enhancing potential will be highlighted to WADA and confidential scientific data relating to them would be transferred by GSK so anti-doping experts can begin work on detection methods.

4th July 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...